Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of SLN360 in adults with elevated lipoprotein(a) at high risk of atherosclerotic cardiovascular disease events
NL-OMON53716Phase 2Recruiting
- Sponsor
- Silence Therapeutics
- Start
- Dec 2022
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atherosclerotic disease and lipoprotein(a) hyperlipoproteinemia (Lp(a)) comparing SLN360 with Placebo (2 arms). Primary endpoint: Time-averaged change in lipoprotein(a) from baseline to Week 36. Started Dec 2022; status: recruiting.
02
Drugs
zerlasiran
03
Conditions
atherosclerotic diseaselipoprotein(a) hyperlipoproteinemia (Lp(a))
Beyond the preview
Go deeper on NL-OMON53716.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON53716.